-transparent.png){kind=logo}
Amiodarone is an effective antiarrhythmic drug for the control of potentially lethal and lethal ventricular arrhythmias (VA). In the United States, a high-dose regimen has been used at the expense of a high toxicity profile for the control of lethal VAs. Significant antiarrhythmic efficacy has also been established with low-dose regimens, which carry a low rate of intolerable side effects (5.4%) when compared with the high-dose regimen (16.7%). The high incidence of tolerable and intolerable adverse side effects is probably related to high amiodarone loading (31.92 g) and maintenance doses (520 mg/d). In contrast, the low-dose regimen uses much lower loading (7.2 g) and maintenance (280 mg/d) doses.
N Z Kerin, and
E Aragon, and
K Faitel, and
H Frumin, and
M Rubenfire
November 1983,
The American journal of cardiology,
N Z Kerin, and
E Aragon, and
K Faitel, and
H Frumin, and
M Rubenfire
January 1983,
European journal of clinical pharmacology,
N Z Kerin, and
E Aragon, and
K Faitel, and
H Frumin, and
M Rubenfire
April 1997,
Clinical cardiology,
N Z Kerin, and
E Aragon, and
K Faitel, and
H Frumin, and
M Rubenfire
December 1999,
Transplantation proceedings,
N Z Kerin, and
E Aragon, and
K Faitel, and
H Frumin, and
M Rubenfire
July 2015,
International journal of radiation oncology, biology, physics,
N Z Kerin, and
E Aragon, and
K Faitel, and
H Frumin, and
M Rubenfire
March 1989,
The Canadian journal of cardiology,
N Z Kerin, and
E Aragon, and
K Faitel, and
H Frumin, and
M Rubenfire
November 2001,
The Annals of thoracic surgery,
N Z Kerin, and
E Aragon, and
K Faitel, and
H Frumin, and
M Rubenfire
February 2003,
Chest,
N Z Kerin, and
E Aragon, and
K Faitel, and
H Frumin, and
M Rubenfire
January 1988,
Chest,
N Z Kerin, and
E Aragon, and
K Faitel, and
H Frumin, and
M Rubenfire
October 2014,
The Cochrane database of systematic reviews,
